- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
With Rise in Obesity, Incidence of Diabetes Sees a Global Spike
The study published in The Lancet found a 45% rise in global diabetes during a study period that spanned more than a decade, between 1999 and 2013.
As the world gets flat with increased globalization, chronic diseases that troubled developed nations have now spread across continents. While the sprad of infectious diseases like malaria and tuberculosis has significantly reduced, the spread of cancer and diabetes is upsetting the economics in nations like India, China, and Mexico.
The study led by the Institute for Health Metrics and Evaluation, drew from more than 35,000 data sources across 188 countries and was funded by the Bill and Melinda Gates Foundation.
While China contributed to the spike in global diabetes—a 56% increase between 1999 and 2013—United States topped the charts with a 71% increase during the study period. Saudi Arabia saw a 60% increase and Mexico saw a 52% increase in the rate of diabetes.
Read the complete article in The New York Times: http://nyti.ms/1T73Q5Y
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
